Alport Nephropathy
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT) (NCT06499948) | Stefan Lujinschi | 2024-02-26 |
| Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy. (NCT03074357) | Novartis Pharmaceuticals | 2017-04-04 |
Track Alport Nephropathy automatically
Every clearance here is in the API, with alerts when new ones post.